NASDAQ · CNSP
CNS Pharmaceuticals, Inc.
$4.77+$0.26 (+5.76%)
CNS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.74% below the high.
Loading market information…
NASDAQ · RDHL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
RedHill Biopharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 73.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
RedHill Biopharma Ltd.’s next earnings report is currently expected on Mar 18, 2027, with estimated earnings per share of -$474.29. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow RedHill Biopharma Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 |
|---|
| Mar 14, 2024 |
| -$0.20-566.67% vs estimate |
| $567.50K-97.79% vs estimate |
| Q3 2023 | Nov 6, 2023 | -$24.00-1,826.62% vs estimate | $567.50K-97.65% vs estimate |
|---|
| Q1 2023 | Jun 30, 2023 | $4.83+305.88% vs estimate | $1.80M-15.0% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.77+$0.26 (+5.76%)
CNS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.74% below the high.
$2.04-$0.06 (-2.86%)
Jaguar Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
$0.83-$0.09 (-9.79%)
Bio Green Med Solution, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.36% below the high.
$7.79-$3.69 (-32.14%)
Flora Growth Corp.’s quoted price sits in the lower half of its reported 52-week range, 83.43% below the high.
$0.95+$0.10 (+11.87%)
60 Degrees Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.01% below the high.
$1.10+$0.03 (+2.8%)
Akanda Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.61% below the high.
$0.16$0.00 (0.0%)
BNB Plus Corp.’s quoted price sits in the lower half of its reported 52-week range, 97.72% below the high.
$1.39-$0.66 (-32.2%)
GlucoTrack, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.33% below the high.
